UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~SEPTEMBER~~MARCH 3031, ~~2018~~2019

¨[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 333-215083

IASO BIOMED, INC. ~~(Exact name of registrant as specified in its charter)~~

(Exact name of registrant as specified in its charter)

Colorado

47-3474169

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification Number)

7315 East Peakview Avenue

Centennial, Colorado 80111

(Address of principal executive offices) (Zip Code)

(720) 389-0650

(Registrant’s telephone number, including area code)

Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. YES [X] x NO ¨ [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES ¨ [ ] NO x [X]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer, “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨[ ] Accelerated filer ¨[ ] Non-accelerated filer ¨[X] Smaller reporting company x[X] ~~(do not check if a smaller reporting company)~~ Emerging growth company x[X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying any new or revised financial accounting standards provided pursuant to Section 14 (a) if the Exchange Act ¨ [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ¨ [ ] NO x [X]

As of ~~November~~May 115, ~~2018~~2019 there were 3537,~~952~~248,~~632~~744 shares of common stock outstanding.

IASO BioMed, Inc.

Table of Contents

		Page	~~Page~~
PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements	2		2
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12		14
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	14		18
Item 4.	Controls and Procedures	15		18
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	15		19
Item 1A.	Risk Factors	15		19
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	15		19
Item 3.	Defaults Upon Senior Securities	15		19
Item 4.	Mine Safety Disclosures	15		19
Item 5.	Other Information	15		19
Item 6.	Exhibits	16		19
	Signatures	17		20

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

IASO BIOMED, INC.
CONDENSED BALANCE SHEETS
SEPTEMBER 30, 2018 AND DECEMBER 31, 2017
(UNAUDITED)
				September 30,		December 31,
				2018		2017
CURRENT ASSETS:
	Cash				$ 177,692		$ 20,191
	Prepaid expenses				2,903		1,562
		Total current assets			180,595		21,753
TOTAL ASSETS					$ 180,595		$ 21,753
LIABILITIES AND SHAREHOLDERS' DEFICIT
CURRENT LIABILITIES:
	Accounts payable				$ 62,590		$ 64,427
	Note payable, related party				60,000		60,000
	Accrued salaries				346,250		187,500
	Accrued board fees				125,000		-
	Accrued interest, related party				4,896		2,203
		Total current liabilities			598,736		314,130
TOTAL LIABILITIES					598,736		314,130
COMMITMENTS AND CONTINGENCIES (Note 5)
STOCKHOLDERS' DEFICIT:
	Preferred stock, $.0001 par value; 10,000,000 shares authorized,
		no shares issued and outstanding			-		-
	Common stock, $.0001 par value, 100,000,00 shares authorized;
		35,952,632 and 34,252,632 shares issued and outstanding			3,595		3,425
	Additional paid-in capital				1,932,010		1,108,126
	Accumulated deficit				(2,353,746)		(1,403,928)
			Total shareholders' deficit		(418,141)		(292,377)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT					$ 180,595		$ 21,753

IASO BIOMED, INC.

2CONDENSED BALANCE SHEETS

IASO BIOMED, INC.
CONDENSED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018 AND 2017
(UNAUDITED)
			For the three months ended			For the nine months ended
			September 30,			September 30,
				2018	2017		2018	2017
Revenues				$ -	$ -		$ -	$ -
Operating expenses:
	General and administrative			186,975	113,788		852,125	439,440
	Research and development			10,000	11,498		95,000	162,576
		Total operating expenses		196,975	125,286		947,125	602,016
Loss From Operations				(196,975)	(125,286)		(947,125)	(602,016)
Other Expenses:
	Interest expense, related party			907	377		2,693	1,121
		Total other expenses		907	377		2,693	1,121
	Net Loss			$ (197,882)	$ (125,663)		$ (949,818)	$ (603,137)
Earnings per Common Share:
	Basic and diluted loss per share			$ (0.01)	$ (0.01)		$ (0.03)	$ (0.02)
Weighted average number of common Shares outstanding:
	Basic and diluted			35,358,882	34,164,116		34,794,024	33,716,070

MARCH 31, 2019 AND DECEMBER 31, 2018

3(UNAUDITED)

IASO BIOMED, INC.
	March 31,				December 31,
CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT
	2019				2018
NINE MONTHS ENDED SEPTEMBER 30, 2018
CURRENT ASSETS:
(UNAUDITED)
Cash	$	78,174			$	140,234
						ADDITIONAL
Prepaid expenses		-				1,451
		COMMON STOCK				PAID-IN		ACCUMULATED
Total current assets		78,174				141,685
		SHARES		AMOUNT		CAPITAL		DEFICIT	TOTAL
TOTAL ASSETS	$	78,174			$	141,685
BALANCE, December 31, 2017		34,252,632		3,425		1,108,126		(1,403,928)	(292,377)
LIABILITIES AND SHAREHOLDERS’ DEFICIT
Sale of common stock		1,275,000		127		407,373		-	407,500
CURRENT LIABILITIES:
Warrant exercises		425,000		43		4,207		-	4,250
Accounts payable	$	133,400			$	92,901
Share-based compensation		-		-		412,304		-	412,304
Accounts payable, related party		55,000				43,000
Net loss		-		-		-		(949,818)	(949,818)
Note payable, related party		60,000				60,000
BALANCE, September 30, 2018		35,952,632		$ 3,595		$ 1,932,010		$ (2,353,746)	$ (418,141)
Accrued salaries		458,750				402,500
Accrued board fees		155,000				140,000
Accrued interest, related party		6,691				5,803
Total current liabilities		868,841				744,204
TOTAL LIABILITIES		868,841				744,204
COMMITMENTS AND CONTINGENCIES (Note 5)
STOCKHOLDERS’ DEFICIT:
Preferred stock, $.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding		-				-
Common stock, $.0001 par value, 100,000,00 shares authorized; 37,248,744 and 35,952,632 shares issued and outstanding		3,725				3,595
Additional paid-in capital		2,437,432				2,435,051
Accumulated deficit		(3,231,824	)			(3,041,165	)
Total shareholders’ deficit		(790,667	)			(602,519	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	78,174			$	141,685

4See accompanying notes to these condensed financial statements

IASO BIOMED, INC.
CONDENSED STATEMENT OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2018 AND 2017
(UNAUDITED)
				For the nine months ended September 30,
				2018	2017
Cash Flows from Operating Activities:
	Net loss			$ (949,818)	$ (603,137)
	Adjustments to reconcile net loss to net cash used in operating activities:
			Share-based compensation	412,304	193,693
			Contributed services	-	5,000
		Changes in assets and liabilities:
			Prepaid expenses	(1,340)	(1,576)
			Accounts payable	(1,838)	80,808
			Accrued salaries	158,750	131,250
			Accrued board fees	125,000	-
			Accrued interest, related party	2,693	1,118
		Net cash used in operating activities		(254,249)	(192,844)
Cash Flows from Financing Activities:
	Proceeds from issuance of notes payable, related party			-	18,000
	Payments on notes payable, related party			-	(18,000)
	Proceeds from sale of common stock			407,500	211,500
	Proceeds from the exercise of warrants			4,250	2,500
		Net cash provided by financing activities		411,750	214,000
Net Increase (Decrease) in Cash				157,501	21,156
Cash, beginning of period				20,191	13,191
Cash, end of period				$ 177,692	$ 34,347
SUPPLEMENTAL CASH FLOW INFORMATION:
	Cash paid for interest, note payable - officer			$ -	$ 3

5IASO BIOMED, INC.

~~IASO~~CONDENSED STATEMENTS ~~BIOMED,~~OF ~~INC.~~OPERATIONS

~~NOTES~~FOR THE TOTHREE ~~UNAUDITED~~MONTHS ~~CONDENSED~~ENDED ~~FINANCIAL~~MARCH ~~STATEMENTS~~31, 2019 AND 2018

~~1. Nature of Operations and Summary of Significant Accounting Policies:~~(UNAUDITED)

Nature of Operations – IASO BioMed, Inc. (“IASO” or the “Company”) is a developmental stage biotechnology company focusing on researching and developing drugs and diagnostic tests for products with a large commercial market potential as well as drugs that may qualify for orphan drug status. The Company is developing a unique, first in class drug for androgen replacement treatment that it believes will be a safer alternative to currently available testosterone replacement therapy by stimulating the body’s own production rather than using synthetic hormones and steroids. It is also developing a process, or method, which the Company believes will be the basis for developing an early stage blood or fluid test for Alzheimer’s disease. There is no assurance that these research and development activities will result in products that can be sold. The Company was incorporated as a C-corporation in the state of Colorado on March 11, 2015. It has its primary place of business in Denver, Colorado.

	For the three months ended
	March 31,
	2019			2018

Revenues	$	-		$	-

Operating expenses:
General and administrative		137,771			540,357
Professional and consulting expense, related party		17,000			5,000
Research and development		35,000			10,000
Total operating expenses		189,771			555,357

Loss From Operations		(189,771	)		(555,357	)

Other Expenses:
Interest expense, related party		888			888
Total other expenses		888			888

Net Loss	$	(190,659	)	$	(556,245	)

Earnings per Common Share:
Basic and diluted loss per share	$	(0.01	)	$	(0.02	)

Weighted average number of common Shares outstanding:
Basic and diluted		37,048,417			34,527,632

~~Basis~~See accompanying ofnotes ~~presentation - The interim unaudited financial statements presented herein have been prepared pursuant~~ to ~~the~~these rules and regulations of the Securities and Exchange Commission (“SEC”) as of and for the three and nine month periods ended September 30, 2018 and 2017. The December 31, 2017 Balance Sheet included herein was derived from the audited year-end financial statements of the Company. Certain information and footnote disclosures normally included in unaudited financial statements prepared in accordance with generally accepted accounting principles have been condensed ~~or omitted pursuant to such rules and regulations. The interim unaudited~~ financial statements should be read in conjunction with the Company’s annual financial statements for the year ended December 31, 2017, notes and accounting policies thereto included in the Company’s Annual Report on Form 10-K.

In the opinion of management, all adjustments (consisting only of normal recurring adjustments) which are necessary to provide a fair presentation of operating results for the interim periods presented have been made. The results of operations for the periods presented are not necessarily indicative of the results to be expected for the year.3

~~Cash and Cash Equivalents – For purposes of the statements of cash flows~~IASO BIOMED, ~~the Company considers all highly liquid debt instruments purchased with an original maturity of six months or less to be cash equivalents~~INC.

~~Use~~CONDENSED STATEMENT ofOF ~~Estimates – The preparation of the Company~~STOCKHOLDERS’s financial statements, in conformity with generally accepted accounting principles, requires the Company’s management to make estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. Actual results could differ from those estimates. Significant items subject to such estimates include but are not limited to the valuation of share-based awards.DEFICIT

~~Research~~THREE MONTHS ~~and~~ENDED ~~Development~~MARCH ~~Costs – Research and development costs are charged to operations in the period incurred. For the nine months ended September 30~~31, 2018 ~~and~~AND ~~2017, the Company incurred $95,000 and $162,576 in research and development costs, respectively.~~2019

Share-based Compensation – Share-based payments are measured at their estimated fair value on the date of grant. Share-based awards to non-employees are re-measured at fair value each financial reporting date until performance is completed. Share-based compensation expense recognized during a period is based on the estimated number of awards that are ultimately expected to vest. For warrants that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested warrants on a straight-line basis over the remaining vesting period.(UNAUDITED)

The Company uses the Black-Scholes option-pricing model to estimate the fair value of warrants and the market price of our common stock, or comparable public companies if our stock is not trading, on the date of grant for the fair value. Our determination of fair value of share-based awards is affected by those stock prices as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and certain other market variables such as the risk-free interest rate.

					ADDITIONAL
	COMMON STOCK				PAID-IN		ACCUMULATED
	SHARES		AMOUNT		CAPITAL		DEFICIT			TOTAL
BALANCE, January 1, 2018		33,252,632		3,425		1,108,126		(1,403,928	)		(292,377	)
Sale of common stock		250,000		25		99,975		-			100,000
Warrant exercises		400,000		40		3,960		-			4,000
Share-based compensation		-		-		357,428		-			357,428
Net loss		-		-		-		(556,245	)		(556,245	)
BALANCE, March 31, 2018		33,902,632	$	3,490	$	1,569,489	$	(1,960,173	)	$	(387,194	)

BALANCE, January 1, 2019		35,952,632	$	3,595	$	2,435,051	$	(3,041,165	)	$	(602,519	)
Warrant exercises		1,296,112		130		2,381		-			2,511
Net loss		-		-		-		(190,659	)		(190,659	)
BALANCE, March 31, 2019		37,248,744	$	3,725	$	2,437,432	$	(3,231,824	)	$	(790,667	)

6See accompanying notes to these condensed financial statements

~~IASO BIOMED, INC.~~4

~~NOTES~~IASO BIOMED, ~~TO UNAUDITED CONDENSED FINANCIAL STATEMENTS~~INC.

~~Income~~CONDENSED STATEMENT ~~Taxes~~OF –CASH The Company accounts for income taxes under the liability method, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.FLOWS

~~Fair~~FOR THE ~~Value~~THREE ofMONTHS ~~Financial~~ENDED ~~Instruments~~MARCH –31, ~~The~~2019 ~~carrying~~AND ~~value of cash and cash equivalents and trade accounts payable are considered to approximate fair value due to the short-term nature of these instruments.~~2018

Earnings Per Share – Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes, if any. There were 11,135,000 and 8,710,000, respectively, shares excluded as they were anti-dilutive at September 30, 2018 and 2017.(UNAUDITED)

Recently Issued Accounting Pronouncements– In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (Topic 842), which requires lessees to recognize a right of use asset and related lease liability for those leases classified as operating leases at the commencement date and have lease terms of more than 12 months. This topic retains the distinction between finance leases and operating leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those years, and must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Although the Company currently has no lease obligations, it will adopt the new requirements if it enters into a lease obligation.

	For the three months ended March 31,
	2019			2018

Cash Flows from Operating Activities:
Net loss	$	(190,659	)	$	(556,245	)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation		-			357,428
Changes in assets and liabilities:
Prepaid expenses		1,451			1,407
Accounts payable		52,499			(30,930	)
Accrued salaries		56,250			56,250
Accrued board fees		15,000			105,000
Accrued interest, related party		888			888
Net cash used in operating activities		(64,571	)		(66,202	)

Cash Flows from Financing Activities:
Proceeds from sale of common stock		-			100,000
Proceeds from the exercise of warrants		2,511			4,000
Net cash provided by financing activities		2,511			104,000

Net Increase (Decrease) in Cash		(62,060	)		37,798
Cash, beginning of period		140,234			20,191
Cash, end of period	$	78,174		$	57,989

InSee accompanying ~~August~~notes 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides guidance on how certain cash receipts and cash payments should be presented and classified in the statement of cash flows with the objective of reducing existing diversity in practice with respect to these ~~items.~~condensed ASU 2016-15 is effective for annual periods, and interim periods within those years, beginning after December 15, 2017. This standard will not have a material impact on the Company’s results of operations or financial ~~position.~~statements

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force), which provides guidance on the presentation of restricted cash or restricted cash equivalents in the statement of cash flows. For public companies, these amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The adoption of ASU 2016-18 is not expected to have a material impact on the financial statements.5

~~In May 2017~~IASO BIOMED, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modificationINC. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending September 30, 2019 and interim periods within that annual period. Early adoption is permitted. The Company does not expect ASU 2017-09 will have a significant impact on its financial statements upon adoption.

7NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

~~IASO~~1. Nature ~~BIOMED,~~of ~~INC.~~Operations and Summary of Significant Accounting Policies:

~~NOTES~~Nature of TOOperations ~~UNAUDITED~~– ~~CONDENSED~~IASO ~~FINANCIAL~~BioMed, ~~STATEMENTS~~Inc. (“IASO” or the “Company”) is a developmental stage biotechnology company focusing on researching and developing drugs and diagnostic tests for products with a large commercial market potential as well as drugs that may qualify for orphan drug status. The Company is primarily developing a peptide as a testosterone replacement therapy by stimulating the body’s own production of testosterone rather than using synthetic steroid hormones. The Company believes this peptide may be a safer alternative – to be proven after clinical studies - to currently available interventions for restoring testosterone levels in males. A second program of the Company is a test for dementia we believe will be the basis for developing an early stage blood or fluid test for Alzheimer’s disease and other similar conditions; the dementia test remains an asset of the Company which the Company will be seeking to out-license to a 3rd party for further development and commercialization. There is no assurance that these research and development activities will result in products that can be sold. The Company was incorporated as a C-corporation in the state of Colorado on March 11, 2015. It has its primary place of business in Denver, Colorado.

2Basis of presentation - The interim unaudited financial statements presented herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) as of and for the three-month periods ended March 31, 2019 and 2018. ~~Going~~The ~~Concern:~~December 31, 2018 Balance Sheet included herein was derived from the audited year-end financial statements of the Company. Certain information and footnote disclosures normally included in unaudited financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The interim unaudited financial statements should be read in conjunction with the Company’s annual financial statements for the year ended December 31, 2018, notes and accounting policies thereto included in the Company’s Annual Report on Form 10-K.

~~At September 30, 2018 and December 31, 2017,~~ In the ~~Company~~opinion ~~had cash~~ of ~~$177~~management,~~692~~ ~~and~~all ~~$20,191,~~adjustments ~~respectively.~~(consisting Itonly ~~also had a working capital deficit~~ of ~~$418,141~~normal ~~and~~recurring ~~$292,377,~~adjustments) ~~respectively~~which ~~and~~are annecessary ~~accumulated deficit of $2,353,746 and $1,403,928, respectively. This raises substantial doubt about the Company's ability~~ to ~~continue~~provide as a fair ~~going~~presentation ~~concern.~~of ~~Management~~operating isresults ~~taking action to ensure the Company will continue as a going concern~~ for ~~at least one year beyond~~ the ~~date~~interim ofperiods ~~the~~presented ~~issuance~~have ofbeen ~~the Company’s financial statements~~made. ~~From~~The ~~March~~results ~~11,~~of ~~2015~~operations (Inception) through September 30, 2018, the Company has sold $971,842 in common stock. Common stock sales continue pursuant to the Company’s private placement offering. Additionally, the Company received approval for ~~its Form S-1 Registration Statement with~~ the ~~Securities~~periods presented ~~and~~are ~~Exchange~~not ~~Commission,~~necessarily ~~through~~indicative ~~which it may offer for sale additional shares~~ of ~~its common stock. These fundraising efforts may not be successful. While there can be no assurances, management believes that these actions will enable~~ the ~~Company~~results to ~~continue as a going concern. The financial statements do not include any adjustments that might~~ be ~~necessary~~expected iffor the ~~Company is unable to continue as a going concern~~year.

3.Reclassification – ~~Related~~Certain ~~Party~~prior ~~Transactions:~~period amounts have been reclassified to conform with the current period presentation.

~~Note~~Cash and ~~Payable~~Cash Equivalents – InFor ~~October~~purposes ~~2016,~~of the ~~Company~~statements ~~executed~~of ancash ~~unsecured note payable to Richard Schell~~flows, the Company’s ~~Chief~~considers ~~Executive~~all ~~officer,~~highly ~~founder~~liquid debt ~~and~~instruments ~~stockholder~~purchased ~~for~~with ~~$25,000~~an ~~bearing~~original ~~interest~~maturity atof 6%six ~~per~~months ~~annum,~~or ~~which~~less ~~remained~~to ~~outstanding~~be atcash ~~September 30, 2018 and December 31, 2017 with accrued interest payable of $2,819 and $1,697, respectively~~equivalents.

InUse of ~~October~~Estimates ~~2017,~~– The preparation of the Company’s ~~executed~~financial anstatements, ~~unsecured~~in ~~promissory~~conformity ~~note~~with togenerally ~~Richard~~accepted accounting ~~Schell~~principles, ~~for~~requires ~~$35,000~~the ~~bearing~~Company’s ~~interest~~management atto 6%make ~~per~~estimates ~~annum,~~and ~~which~~assumptions ~~remained~~that ~~outstanding~~affect atthe ~~September~~amounts ~~30,~~reported in ~~2018~~these financial statements and ~~December~~accompanying ~~31,~~notes. ~~2017~~Actual ~~with~~results ~~accrued~~could ~~interest~~differ ~~payable~~from ofthose ~~$2,077~~estimates. ~~and~~Significant ~~$506,~~items ~~respectively~~subject to such estimates include but are not limited to the valuation of share-based awards.

AResearch and ~~total~~Development ofCosts ~~$2,693~~– Research and ~~$1,121~~development ofcosts ~~interest~~are ~~expense~~charged ~~was~~to ~~accrued~~operations ~~during~~in the ~~nine-month~~period ~~periods~~incurred. For the three months ended ~~September~~March 3031, 2019 and 2018, the Company incurred $35,000 and ~~2017~~$10,000 in research and development costs, respectively.

~~Employment~~Share-based Compensation ~~Agreements~~ – InShare-based ~~March~~payments ~~2017~~are ~~the~~measured ~~Company~~at ~~entered~~their ~~into~~estimated anfair ~~employment~~value ~~agreement~~on ~~with~~the ~~its~~date ~~CEO~~of ~~for~~grant. ~~a two~~Share-~~year~~based awards ~~term.~~to ~~The~~non-employees ~~base~~are ~~salary~~re-measured ofat ~~$150,000~~fair ~~per~~value ~~annum~~each isfinancial ~~payable~~reporting todate ~~the~~until ~~CEO~~performance ~~only~~is ~~upon the Company’s raising of an additional $750,000~~completed. ~~Mr.~~Share-based compensation ~~Schell~~expense ~~will~~recognized ~~assume~~during ~~his responsibilities on~~ a ~~part~~period ~~time~~is ~~basis~~based ~~until~~on ~~requested by~~ the ~~Board~~estimated number of ~~Directors~~awards tothat ~~become~~are aultimately ~~full-time~~expected ~~executive~~to vest. For ~~The CEO also received~~ warrants tothat ~~purchase~~do ~~250,000~~not ~~shares~~vest ofimmediately ~~the~~but ~~Company’s~~which ~~common~~contain ~~stock~~only ~~at $0.40 per share for~~ a ~~period~~service ofvesting ~~five years after issuance. 125~~feature,~~000~~ ~~warrants~~we ~~vested~~recognize ~~upon~~compensation ~~signing~~cost on the ~~agreement~~unvested ~~and~~warrants ~~the~~on ~~remaining~~a ~~125,000~~straight-line ~~vested~~basis inover ~~March 2018. The CEO will also be eligible to earn discretionary annual performance bonuses upon meeting certain objectives as determined by~~ the ~~Board~~remaining ofvesting ~~Directors~~period. ~~The agreement provides for severance payments.~~

InThe Company ~~March~~uses ~~2017~~ the ~~Company~~Black-Scholes ~~entered~~option-pricing ~~into~~model anto ~~employment~~estimate ~~agreement~~the ~~with~~fair ~~its~~value ~~CFO~~of ~~for~~warrants aand ~~two-year~~the ~~term.~~market ~~The~~price ~~CFO~~of ~~will~~our ~~assume~~common stock, ~~his~~or ~~responsibilities~~comparable onpublic acompanies ~~part~~if ~~time~~our ~~basis~~stock ~~until~~is ~~requested~~not bytrading, on the ~~Board~~date of ~~Directors~~grant tofor ~~become~~the afair ~~full-time executive~~value. ~~The~~Our ~~base~~determination of ~~salary~~fair value of ~~$75,000~~share-based ~~per~~awards ~~annum~~ is ~~payable~~affected toby ~~the~~those ~~CFO~~stock ~~only~~prices ~~upon~~as ~~the~~well ~~Company’s~~as ~~raising~~assumptions ofregarding ~~an additional $750,000. When the CFO becomes~~ a ~~full-time~~number ~~executive,~~of ~~his~~highly ~~salary~~complex and ~~will~~subjective bevariables. ~~increased~~These tovariables ~~$125~~include,~~000~~ ~~per~~but ~~annum.~~are ~~The~~not ~~CFO~~limited ~~also received warrants~~ to ~~purchase 500~~,~~000~~ ~~shares~~our ofexpected ~~the Company’s common~~ stock atprice ~~$0.40~~volatility ~~per~~over ~~share~~the ~~for~~term ~~a period~~ of the ~~five years after issuance. 250~~awards,~~000~~ ~~warrants vested upon signing the agreement~~ and ~~the~~certain ~~remaining~~other ~~250,000~~market ~~vested~~variables insuch ~~March 2018. The CFO will also be eligible to earn discretionary annual performance bonuses upon meeting certain objectives~~ as ~~determined by~~ the ~~Board~~risk-free ofinterest ~~Directors~~rate. ~~The agreement provides for severance payments.~~

The Company accrued $168,750 and $131,250 in salaries related to these agreements for the nine-month periods ended September 30, 2018 and 2017, respectively. During the nine month period ended September 30, 2018, $10,000 was paid to these officers from fees accrued under these agreements.6

8IASO BIOMED, INC.

~~IASO~~NOTES TO ~~BIOMED,~~UNAUDITED ~~INC.~~CONDENSED FINANCIAL STATEMENTS

~~NOTES~~Income Taxes TO– ~~UNAUDITED~~The ~~CONDENSED~~Company ~~FINANCIAL~~accounts ~~STATEMENTS~~for income taxes under the liability method, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.

~~Contributed~~Fair Value ~~Services~~of –Financial ~~The~~Instruments ~~Company's~~– ~~CEO and CFO were not paid a salary during the period from March 11, 2015 (inception) through February 28, 2017.~~ The ~~Company~~carrying ~~recognized the~~ value of ~~their~~cash ~~services~~and ascash ~~contributed~~equivalents ~~services~~and bytrade ~~recognizing~~accounts ~~$5,000~~payable ofare considered ~~compensation~~to ~~expenses in~~approximate ~~general~~fair ~~and~~value ~~administration~~due ~~expenses in~~to the ~~statement~~short-term nature of ~~operations~~these ~~for the nine months ended September 30, 2017~~instruments.

~~Scientific~~Earning (Loss) ~~Advisory~~Per ~~Board~~Share ~~Agreements~~– -Basic ~~Effective~~loss ~~March~~per 1,common ~~2018,~~share ~~the~~is ~~Company~~computed ~~entered~~by ~~into~~dividing anet ~~Scientific~~loss ~~Advisory~~by ~~Board Agreement with our director Dr. Papadopoulos (~~the ~~“Papadopoulos~~weighted ~~Agreement”),~~average ~~through~~number ~~which~~of vested ~~Dr.~~common ~~Papadopoulos~~shares ~~agreed~~outstanding toduring ~~serve~~the ~~on our Scientific Advisory Board~~period. ~~The~~Diluted ~~term~~loss ofper ~~the~~common ~~Papadopoulos~~share ~~Agreement~~ is ~~one~~computed ~~year~~by ~~from~~dividing ~~execution~~net ~~and~~loss ~~may be renewed annually~~ by ~~mutual~~the ~~consent~~weighted average ofnumber ~~both parties. The Papadopoulos Agreement provides for payments as follows: an annual fee~~ of ~~$35,000,~~vested ~~which~~common ~~includes~~shares ~~$10~~outstanding,~~000~~ toplus ~~serve as~~ the ~~Scientific~~impact ~~Advisory~~of ~~Board~~common ~~Chairman;~~shares, aif ~~signing bonus of $50~~dilutive,~~000~~ ~~payable~~resulting ~~after~~from ~~successful~~the ~~closing~~ exercise of ~~any~~outstanding ~~cumulative~~stock ~~minimum~~options $1and warrants,~~000,000~~ ~~investment~~plus in the ~~Company;~~conversion ~~a non-discretionary bonus~~ of ~~$45~~convertible notes,~~000~~ ~~payable~~if ~~following~~any. aThere ~~successful~~were ~~financing round of a minimum of $2~~11,~~000~~100,000; and ~~should the Papadopoulos Agreement be renewed after one year~~9, ~~a $95~~620,000, respectively, ~~bonus~~shares ~~payable~~excluded ~~only~~as ~~after~~they ~~the~~were ~~signing bonus and non~~anti-~~discretionary~~dilutive ~~bonus~~at ~~from~~March year one have been earned. In order to receive the non-discretionary bonus payments Dr. Papadopoulos must be actively involved in the creation and execution of strategies necessary for the Company to achieve its strategic plan including the scientific31, ~~commercial~~2019 and ~~business objectives, as applicable and as agreed upon between the Dr~~2018. ~~Papadopoulos and the Company’s Chief Executive Officer.~~

~~Also,~~Recently Issued ~~effective~~Accounting ~~March~~Pronouncements 1,– ~~2018,~~In weFebruary ~~entered~~2016, ~~into~~the aFinancial ~~Scientific~~Accounting ~~Advisory~~Standards Board ~~Agreement~~(“FASB”) issued ~~with~~Accounting ~~our~~Standards ~~director~~Update ~~Dr. Karatzas~~ (~~the~~ “~~Karatzas Agreement~~ASU”) 2016-02, ~~through~~Leases ~~which~~(Topic ~~Dr.~~842), ~~Karatzas~~which ~~agreed~~requires lessees to ~~serve~~recognize a onright ~~our~~of ~~Scientific~~use ~~Advisory~~asset ~~Board.~~and ~~The~~related ~~term~~lease ofliability ~~the~~for ~~Karatzas~~those ~~Agreement~~leases isclassified ~~one~~as ~~year~~operating ~~from~~leases ~~execution~~at ~~and~~the ~~may~~commencement bedate ~~renewed~~and have ~~annually~~lease byterms ~~mutual~~of ~~consent~~more ofthan ~~both~~12 ~~parties~~months. ~~The~~This ~~Karatzas~~topic ~~Agreement~~retains ~~provides~~the ~~for~~distinction ~~payments~~between asfinance ~~follows:~~leases anand ~~annual~~operating ~~fee~~leases. ofASU ~~$25,000;~~2016-02 is aeffective ~~signing~~for ~~bonus~~fiscal ofyears ~~$50,000~~beginning ~~payable~~ after ~~successful~~December ~~closing of any cumulative minimum $1~~15,~~000,000~~ ~~investment in the Company; a non-discretionary bonus of $40~~2018,~~000~~ ~~payable~~and ~~following~~interim aperiods ~~successful~~within ~~financing~~those ~~round of a minimum of $2~~years,~~000,000;~~ and ~~should~~must ~~the~~apply ~~Karatzas~~a ~~Agreement~~modified retrospective betransition ~~renewed~~approach ~~after~~for ~~one~~leases ~~year,~~existing ~~a $90~~at,~~000~~ ~~bonus~~or ~~payable~~entered ~~only~~into after, the ~~signing~~beginning ~~bonus~~of ~~and non-discretionary bonus from year one have been earned. In order to receive~~ the ~~non-discretionary~~earliest ~~bonus~~comparative ~~payments~~period presented ~~Dr. Karatzas must be actively involved~~ in the ~~creation~~financial ~~and~~statements. ~~execution~~Although ~~of strategies necessary for~~ the Company tocurrently ~~achieve~~has ~~its~~no ~~strategic~~lease ~~plan including the scientific~~obligations, ~~commercial~~it ~~and~~will ~~business~~adopt ~~objectives, as applicable and as agreed upon between~~ the ~~Dr.~~new ~~Karatzas~~requirements if ~~and~~it ~~the~~enters ~~Company’s~~into ~~Chief~~a ~~Executive~~lease ~~Officer~~obligation.

~~The~~In August ~~Company~~2016, ~~accrued~~the aFASB ~~total~~issued ofASU ~~$135~~2016-15,~~000~~ inStatement ~~fees~~of ~~related~~Cash toFlows ~~these~~(Topic ~~agreements~~230): ~~for~~Classification ~~the~~of ~~nine-month~~Certain ~~period~~Cash ~~ended~~Receipts ~~September~~and Cash ~~30,~~Payments. ~~2018,~~ASU ~~which~~2016-15 ~~includes~~provides ~~$35,000~~guidance inon ~~fees~~how certain cash receipts and ~~$100,000~~cash payments should be presented and classified in ~~signing~~the ~~bonuses. The~~statement ~~company~~of ~~paid~~cash aflows ~~total~~with the objective of ~~$10,000~~reducing existing diversity in ~~accrued~~practice ~~fees~~with ~~under~~respect to these ~~agreements~~items. ~~during~~ASU 2016-15 ~~the~~is ~~nine~~effective ~~month~~for ~~period~~annual ~~ended~~periods, ~~September~~and 30interim periods within those years, ~~2018~~beginning after December 15, 2017. This standard will not have a material impact on the Company’s results of operations or financial position.

~~Services~~In May ~~Agreement~~2017, –the ~~Effective~~FASB ~~January~~issued 1,ASU 2017-09, ~~the~~Compensation-Stock ~~Company~~Compensation ~~pays~~(Topic ~~the~~718): ~~Company's~~Scope ~~Corporate~~of ~~Secretary's~~Modification ~~company~~Accounting, ~~$400~~which ~~per~~clarifies when ~~month~~to account for ~~reimbursement~~a change to the terms or conditions of ~~certain~~a ~~administrative~~share-based ~~charges~~payment ~~such~~award as ~~computer~~a modification. Under the new guidance, modification ~~internet~~accounting is required only if the fair value, ~~phone~~the ~~and~~vesting ~~similar~~conditions, ~~items.~~or ~~The~~the ~~agreement~~classification isof onthe aaward ~~month-to-month~~(as ~~basis~~equity or ~~and~~liability) ~~may~~changes beas ~~terminated~~a atresult ~~any~~of ~~time~~the bychange ~~either~~in ~~party~~terms or conditions. ~~Total~~It ~~expense~~is effective prospectively for the ~~nine~~annual ~~months~~period ~~ended~~ ending September 30, ~~2018~~2019 and interim periods within that annual period. Early adoption is permitted. The Company does not expect ASU 2017-09 ~~was~~will ~~$3,600~~have a significant impact on its financial statements upon adoption.

42. Going ~~Stockholders’ Equity~~Concern:

~~The~~At March ~~Company~~31, ~~has~~2019 ~~the~~and ~~authority~~December to31, ~~issue 110~~2018,~~000,000~~ ~~shares~~the Company had cash of $78,174 and $140,234, respectively.~~0001~~ ~~par~~It ~~value~~also ~~stock,~~had a working capital deficit of ~~which~~$790,667 ~~100~~and $602,~~000~~519,~~000~~ ~~shares~~respectively ~~are~~and ~~common~~an ~~stock~~accumulated deficit of $3,231,824 and 10$3,~~000~~041,~~000~~165, ~~shares~~respectively. ~~are~~This ~~preferred~~raises substantial ~~stock~~doubt about the Company’s ability to continue as a going concern. AsManagement is taking action to ensure the Company will continue as a going concern for at least one year beyond the date of ~~September~~the ~~30,~~issuance ~~2018,~~of ~~and~~the ~~December 31~~Company’s financial statements. From March 11, ~~2017~~2015 ~~there~~(Inception) ~~were~~through 35March 31,~~952~~ 2019,~~632~~ ~~and~~the 34Company sold $971,~~252,632~~842 in common stock. ~~shares~~Common ~~issued~~stock sales continue pursuant to private placement and ~~outstanding~~other potential equity offerings. These fundraising efforts may not be successful. While there can be no assurances, management believes that these actions will enable the Company to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

~~For the nine-month period ended September 30~~IASO BIOMED, ~~2018, the Company sold a total of $407,500 through private placements as follows: 250,000 shares of our common stock at $0~~INC.40 per share that included warrants to purchase up to 250,000 shares of our common stock exercisable at $0.75 per share for a period of three years from issuance; and 1,025,000 shares of our common stock at $0.30 per share that included warrants to purchase up to 1,025,000 shares of our common stock exercisable at $0.05 per share for a period of three years from issuance.

~~During~~NOTES TO ~~the~~UNAUDITED ~~nine-month~~CONDENSED ~~period~~FINANCIAL ended September 30, 2018, the Company issued warrants to purchase up to 860,000 shares of common stock at an exercise price of $0.01 per share to business, legal and scientific consultants; 400,000 of which were to expire in December 2022 and 460,000 of which expire in February 2021. Subsequent to issuance, 425,000 of these warrants were exercised for proceeds to the Company of $4,250. We incurred stock compensation expense totaling $336,926 in connection with the issuance of these warrants as more fully explained in Note 6 – Share-based Compensation.STATEMENTS

~~During the nine-month period ended September 30, 2018, the Company issued warrants to purchase up to 140,000 shares of common stock at an exercise price of $0~~3.01 Related ~~per~~Party share, and expire in September 2019, through execution of agreements with new members of our Scientific Advisory Board. We incurred stock compensation expense totaling $54,876 in connection with the issuance of these warrants as more fully explained in Note 6 – Share-based Compensation.Transactions:

5.Note Payable ~~Commitments~~– In October 2016, the Company executed an unsecured note payable to Richard Schell, the Company’s Chief Executive officer, founder and ~~Contingencies:~~stockholder for $25,000 bearing interest at 6% per annum, which remained outstanding at March 31, 2019 and December 31, 2018 with accrued interest payable of $3,567 and $3,197, respectively.

~~Royalties –~~ In October ~~January 2016~~2017, the Company ~~signed~~executed aan ~~license~~unsecured ~~agreement~~promissory ~~with~~note ~~The~~to ~~Royal~~Richard ~~Institution~~Schell for ~~the~~$35,000 ~~Advancement~~bearing ofinterest ~~Learning/McGill~~at ~~University~~6% inper ~~Canada on the Company’s potential products. This agreement requires~~annum, which ~~for~~remained ~~each~~outstanding ofat ~~the~~March ~~Company’s potential products~~31, a2019 3%and ~~payment~~December ~~of annual net revenues~~31, 2018 with aaccrued ~~minimum~~interest ~~royalty~~payable of ~~CAD~~ $53,~~000~~124 ~~each~~and $2,606, ~~per year starting on the date of commercialization of the first product developed using the intellectual property covered by the license agreement~~respectively. ~~The Company must pay milestone payments for the androgen replacement treatment as follows:~~

·A total ~~CAD $5,000 on the issuance~~ of ~~the first US patent · CAD~~ $~~25,000~~888 ~~on the filing~~ of aninterest ~~investigational~~expense ~~new~~was ~~drug~~accrued ~~application~~during oreach ~~regulatory filing · CAD $50,000 on the initiation~~ of the ~~first~~three-month ~~Phase~~periods IIended ~~clinical~~March ~~study · CAD $100~~31,~~000~~ on2019 ~~the~~and ~~initiation of the first Phase III clinical study · CAD $300~~2018,~~000~~ ~~on receipt of regulatory approval~~respectively.

~~The~~Employment Agreements – In March 2017 the Company ~~must~~entered ~~also~~into ~~pay~~an ~~milestone~~employment ~~payments~~agreement aswith ~~follows~~its CEO for a two-year term, which was extended by our board of directors in January 2019 for an additional two-year term until March 2021. The base salary of $150,000 per annum is payable to the ~~out~~CEO only upon the Company’s raising of ~~body~~an ~~test~~additional $750,000. Mr. Schell will assume his responsibilities on a part time basis until requested by the Board of Directors to ~~identify~~become ~~Alzheimer~~a full-time executive. The CEO also received warrants to purchase 250,000 shares of the Company’s ~~disease~~common stock at $0.40 per share for a period of five years after issuance. 125,000 warrants vested upon signing the agreement and the remaining 125,000 vested in March 2018. The CEO will also be eligible to earn discretionary annual performance bonuses upon meeting certain objectives as determined ~~follows:~~by the Board of Directors, none of which have been granted to date. The agreement provides for severance payments.

·In March ~~CAD~~2017 $5the Company entered into an employment agreement with its CFO for a two-year term,~~000~~ which term was extended by our board of directors in January 2019 for an additional two-year term until March 2021. The CFO will assume his responsibilities on a part time basis until requested by the ~~issuance~~Board of ~~the~~Directors ~~first~~to USbecome ~~patent~~a ·full-time ~~CAD~~executive. The base salary of $5075,000 onper annum is payable to the ~~filing~~CFO only upon the Company’s raising of an additional $750,000. When the CFO becomes a ~~510(k)~~full-time orexecutive, his ~~PMA~~salary ~~application~~will ·be ~~CAD~~increased to $~~200~~125,000 onper ~~receipt~~annum. The CFO also received warrants to purchase 500,000 shares of ~~regulatory~~the ~~approval~~Company’s common stock at $0.40 per share for a period of five years after issuance. 250,000 warrants vested upon signing the agreement and the remaining 250,000 vested in March 2018. The CFO will also be eligible to earn discretionary annual performance bonuses upon meeting certain objectives as determined by the Board of Directors, none of which have been granted to date. The agreement provides for severance payments.

~~In addition, the~~ The Company ~~issued~~accrued ~~5% of the total number of issued and outstanding shares in the Company’s Series A financing to the same institution~~$56,250 ~~or 1,652,632 shares~~ in ~~March~~salaries ~~2016.~~related ~~This agreement, payable in Canadian dollars, exposes the Company~~ to ~~foreign~~these ~~exchange~~agreements ~~transaction gains and losses. In August 2016, the Company issued an additional 300,000 shares of the Company’s common stock to McGill~~ in ~~lieu~~each of the ~~pre~~three-~~existing~~month ~~anti-dilution~~periods ~~provision.~~ended AsMarch ~~McGill owns more than 5% of the Company’s outstanding common stock~~31, it2019 isand ~~considered a related party~~2018, respectively.

Scientific Advisory Board Agreements - Effective March 1, 2018, the Company entered into a Scientific Advisory Board Agreement with our director Dr. Papadopoulos (the “Papadopoulos Agreement”), through which Dr. Papadopoulos agreed to serve on our Scientific Advisory Board. The term of the Papadopoulos Agreement is one year from execution and may be renewed annually by mutual consent of both parties. The Papadopoulos Agreement provides for payments as follows: an annual fee of $35,000, which includes $10,000 to serve as the Scientific Advisory Board Chairman; a signing bonus of $50,000 payable after successful closing of any cumulative minimum $1,000,000 investment in the Company; a non-discretionary bonus of $45,000 payable following a successful financing round of a minimum of $2,000,000; and should the Papadopoulos Agreement be renewed after one year, a $95,000 bonus payable only after the signing bonus and non-discretionary bonus from year one have been earned. In order to receive the non-discretionary bonus payments Dr. Papadopoulos must be actively involved in the creation and execution of strategies necessary for the Company to achieve its strategic plan including the scientific, commercial and business objectives, as applicable and as agreed upon between the Dr. Papadopoulos and the Company’s Chief Executive Officer. In January 2019, this agreement was extended for an additional year under the same terms and conditions and will expire in February 2020.

~~IASO BIOMED, INC.~~8

~~NOTES~~IASO BIOMED, ~~TO UNAUDITED CONDENSED FINANCIAL STATEMENTS~~INC.

~~Research~~NOTES TO ~~Agreement–~~UNAUDITED InCONDENSED ~~January~~FINANCIAL 2016 the Company signed a Research Agreement with The Research Institute of the McGill University Health Centre (RIMUHC) in Canada for research activities on the Company’s potential products. The agreement covers a period of one year and required the Company to pay a total of $130,000. The Agreement was amended in March 2017 to extend the term for one year and required the payment of an additional $130,000 over that period. The Company paid these installment payments in July and October 2017 leaving no balance due. The Company agreed in June 2018 to an additional payment of $65,000 to continue research and development activities at RIMUHC, but has not yet extended or amended the prior agreement. This amount was paid in August 2018.STATEMENTS

~~Scientific~~Also, effective ~~Advisory~~March ~~Board~~1, ~~– In September~~ 2018, we ~~executed~~entered ~~agreements~~into ~~with~~a ~~four~~Scientific ~~new~~Advisory ~~members~~Board ofAgreement with our ~~Scientific~~director ~~Advisory~~Dr. ~~Board~~Karatzas (the “~~SAB~~Karatzas Agreement”), through which ~~each~~Dr. ~~new~~Karatzas ~~member~~agreed ~~received~~to aserve ~~warrant~~on toour ~~purchase~~Scientific upAdvisory toBoard. ~~35,000~~The ~~shares~~term of ~~our~~the ~~common~~Karatzas ~~stock~~Agreement is atone anyear ~~exercise~~from ~~price~~execution ofand ~~$0.01~~may ~~per~~be ~~share~~renewed ~~for~~annually aby ~~period~~mutual consent of ~~one~~both ~~year~~parties. In ~~addition,~~The ~~each~~Karatzas ~~new~~Agreement ~~SAB~~provides ~~member~~for payments ~~will~~as befollows: ~~paid~~ an annual fee of $25,000; a signing bonus of $50,000 ~~paid~~payable ~~quarterly~~after successful closing of any cumulative minimum $1,000,000 ~~commencing~~investment ~~with~~in the ~~first~~Company; ~~scheduled~~a ~~SAB~~non-discretionary ~~meeting~~bonus inof ~~November~~$40,000 ~~2018. These~~payable ~~agreements~~following ~~may~~a successful financing round of a minimum of $2,000,000; and should the Karatzas Agreement be renewed ~~annually~~after one year, ~~under~~a ~~the~~$90,000 ~~same~~bonus ~~terms~~payable only after the signing bonus and ~~conditions,~~non-discretionary ~~should~~bonus ~~each~~from ~~member’s~~year ~~appointment~~one have been earned. In order to receive the ~~SAB~~non-discretionary bebonus ~~continued~~payments Dr. We Karatzas ~~incurred~~must ~~stock~~be ~~compensation~~actively ~~cost~~involved in the creation and execution of ~~$54,876~~strategies innecessary ~~connection~~for ~~with~~the Company to achieve its strategic plan including the ~~issuance~~scientific, ofcommercial ~~these~~and ~~warrants~~business objectives, as ~~explained~~applicable ~~more~~and ~~fully~~as inagreed ~~Note~~upon 6between the Dr. ~~Share-based~~Karatzas ~~Compensation~~and the ~~below~~Company’s Chief Executive Officer. In January 2019, this agreement was extended for an additional year under the same terms and conditions and will expire in February 2020.

6.The Company ~~Share~~accrued a total of $15,000 in fees related to these agreements for the three-~~based~~month ~~Compensation~~period ended March 31, 2019, and accrued $105,000 in fees related to these agreements in the three-month period ended March 31, 2018, which included $5,000 in fees and $100,000 in signing bonuses.

InServices Agreement ~~March~~– Effective January 1, 2017, the Company ~~issued~~pays ~~750,000 warrants to~~ the Company’s Corporate ~~officers~~Secretary’s tocompany ~~purchase~~$400 ~~shares~~per month for reimbursement of ~~our~~certain ~~common~~administrative ~~stock~~charges atsuch ~~$0.40~~as ~~per~~computer, ~~share~~internet, phone and similar items. ~~Estimated~~The ~~fair~~agreement ~~values~~is ofon ~~warrants~~a ~~granted~~month-to-month ~~were~~basis ~~determined~~and ~~using~~may ~~the~~be ~~Black-Scholes~~terminated ~~option~~at ~~pricing~~any ~~model~~time ~~with~~by either party. Total expense for the ~~following~~three ~~average~~months ~~assumptions:~~ended March 31, 2019 and 2018 was $1,200.

Risk-free interest rate			1.55%
Expected term			3 years
Volatility			154%
Dividend yield			—
Fair value			$ 0.33

Consulting Agreement and other Payments - Effective March 1, 2018, the Company entered into a Consulting Agreement with our Corporate Secretary through which he will be paid $5,000 per month for a term of two years and is automatically extended on an annual basis unless terminated by either party with thirty days written notice. A total of $15,000 and $5,000 was accrued under this agreement in the three-month periods ended March 31, 2019 and 2018, respectively. In addition, we paid a total of $2,000 to a company controlled by our Corporate Secretary for additional consulting services rendered during the three-month period ended March 31, 2019.

~~Expected~~Warrants - ~~term~~In ~~represents~~October ~~the~~2018, ~~period~~our ~~that~~board ~~the~~of ~~Company’s~~directors ~~stock-based~~issued ~~awards~~our ~~are~~CFO ~~expected~~a warrant to bepurchase ~~outstanding.~~up ~~The~~to ~~Company’s~~950,000 ~~historical~~shares of our common stock for ~~warrant~~a period of three months at an exercise ~~experience~~price ~~does~~of ~~not~~$0.001 ~~provide~~per ashare. ~~reasonable~~These ~~basis~~warrants ~~upon~~were ~~which~~exercised toby ~~estimate~~our ~~expected~~CFO ~~term~~in January 2019. These Aswarrants ~~such,~~were determined by the ~~simplified~~Company ~~method~~to ~~was~~have ~~used~~a tofair ~~calculate~~market value of $379,062 using the ~~expected~~Black-Scholes ~~term~~option pricing model.

~~The~~In October ~~Company~~2018, ~~calculated~~our ~~volatility~~board ~~based~~of ondirectors issued our corporate secretary a warrant to purchase up to 211,112 shares of our common stock for a period of three months at an exercise price of $0.001 per share. These warrants were exercised in January 2019. These warrants were determined by the ~~volatilities~~Company to have a fair market value of ~~comparable~~$84,236 ~~public~~using ~~companies~~the Black-Scholes option pricing model.

~~Total share-based compensation related to these warrants was $20,502 and $162,940 for the nine months ended September 30, 2018 and 2017, respectively~~4. Stockholders’ Equity:

InThe Company ~~February~~has ~~and March 2018~~ the ~~Company~~authority ~~issued warrants~~ to ~~purchase~~issue ~~up to 860~~110,000,000 shares of ~~common stock at an exercise price of~~ $0.010001 ~~per~~par ~~share~~value ~~to business~~stock, ~~legal~~of ~~and~~which ~~scientific consultants; 400~~100,000,000 ofshares ~~which~~are ~~were~~common ~~to expire in December 2022~~ stock and ~~460~~10,000,000 ofshares ~~which~~are ~~expire~~preferred ~~in February 2021~~stock. ~~Estimated~~As ~~fair~~of ~~values~~March of31, ~~warrants~~2019, ~~granted~~and ~~were~~December ~~determined~~31, ~~using~~2018 ~~the~~there ~~Black-Scholes~~were ~~option~~37,248,744 ~~pricing~~and ~~model~~35,952,632 ~~with~~common stock ~~the~~shares ~~following~~issued ~~average~~and ~~assumptions:~~outstanding.

Risk-free interest rate		2.33 – 2.34%
Expected term		2.5 years
Volatility		182-217%
Dividend yield		-
Fair value		$ 0.39

For the three-month period ended March 31, 2018, the Company sold $100,000 in its private placement, issuing 250,000 shares of our common stock at $0.40 per share that included warrants to purchase up to 250,000 shares of our common stock exercisable at $0.75 per share for a period of three years from issuance.

11During the three-month period ended March 31, 2018, the Company issued warrants to purchase up to 860,000 shares of common stock at an exercise price of $0.01 per share to business, legal and scientific consultants; 400,000 of which were to expire in December 2022 and 460,000 of which expire in February 2021. Subsequent to issuance, 400,000 of these warrants were exercised for proceeds to the Company of $4,000. We incurred stock compensation expense totaling $336,926 in connection with the issuance of these warrants as more fully explained in Note 6 – Share-based Compensation.

~~IASO BIOMED, INC.~~9

~~NOTES~~IASO BIOMED, ~~TO UNAUDITED CONDENSED FINANCIAL STATEMENTS~~INC.

~~Expected~~NOTES TO ~~term~~UNAUDITED ~~represents~~CONDENSED ~~the~~FINANCIAL period that the Company’s stock-based awards are expected to be outstanding. The Company’s historical stock warrant exercise experience does not provide a reasonable basis upon which to estimate expected term. As such, the simplified method was used to calculate the expected term.STATEMENTS

~~The~~On November 1, 2018, the Registrant’s Board approved the issuance of warrants to purchase shares of the Company’s ~~calculated~~common stock ~~volatility~~to ~~based~~two onof its executive officers. Mr. Duane C. Knight, Chief Financial Officer of the ~~volatilities~~Registrant, received a warrant to purchase up to 950,000 shares of ~~comparable~~common ~~public~~stock ~~companies~~exercisable for period of three months at an exercise price of $0.001 per share. Mr. Thomas B. Olson, Corporate Secretary of the Registrant, received a warrant to purchase up to 211,112 shares of common stock exercisable for period of three months at an exercise price of $0.001 per share. Messrs. Knight and Olson exercised these warrants in January 2019 for total proceeds to the company of $1,161.

~~Total~~In January ~~share-based~~2019 ~~compensation~~we ~~related~~issued to135,000 ~~these~~shares upon the exercise of warrants ~~was~~to ~~$336~~purchase 135,~~926~~000 shares issued in September and October 2018 at an exercise price of $0.01 per share for ~~the~~total ~~nine~~proceeds ~~months~~to ~~ended~~the ~~September~~Company ~~30,~~of ~~2018~~$1,350.

~~In September 2018 the Company issued warrants to purchase up to 140,000 shares of common stock at an exercise price of $0~~5.01 Commitments ~~per~~and share to new members of our Scientific Advisory that expire in September 2019. Estimated fair values of warrants granted were determined using the Black-Scholes option pricing model with the following average assumptionsContingencies:

Risk-free interest rate		2.49 – 2.57%
Expected term		1.0 years
Volatility		222%
Dividend yield		-
Fair value		$ 0.39

Royalties – In January 2016, the Company signed a license agreement with The Royal Institution for the Advancement of Learning/McGill University in Canada on the Company’s potential products. This agreement requires, for each of the Company’s potential products, a 3% payment of annual net revenues, with a minimum royalty of CAD $5,000 each, per year starting on the date of commercialization of the first product developed using the intellectual property covered by the license agreement. The Company must pay milestone payments for the androgen replacement treatment as follows:

~~Expected~~● ~~term~~CAD ~~represents~~$5,000 on the ~~period~~issuance ~~that~~of the ~~Company’s~~first ~~stock-based~~US ~~awards~~patent ~~are~~that ~~expected~~accrued toUS$3,750 bein ~~outstanding.~~the ~~The~~first ~~Company’s~~quarter ~~historical~~of ~~stock~~2019 ~~warrant~~● ~~exercise~~CAD ~~experience~~$25,000 ~~does~~on ~~not~~the ~~provide~~filing aof ~~reasonable~~an ~~basis~~investigational ~~upon~~new ~~which~~drug toapplication ~~estimate~~or ~~expected~~regulatory ~~term.~~filing As● ~~such~~CAD $50,000 on the ~~simplified~~initiation ~~method~~of ~~was~~the ~~used~~first toPhase ~~calculate~~II clinical study ● CAD $100,000 on the ~~expected~~initiation ~~term.~~of the first Phase III clinical study ● CAD $300,000 on receipt of regulatory approval

The Company ~~calculated~~must ~~volatility~~also ~~based~~pay onmilestone payments as follows for the ~~volatilities~~out of ~~comparable~~body ~~public~~test ~~companies.~~to identify Alzheimer’s disease as follows:

~~Total~~● ~~share-based~~CAD ~~compensation~~$5,000 ~~related~~on tothe ~~these~~issuance ~~warrants~~of ~~was~~the first US patent ● CAD $5450,~~876~~000 ~~for~~on the ~~nine~~filing ~~months~~of ~~ended~~a ~~September~~510(k) 30or PMA application ● CAD $200,000 ~~2018.~~ on receipt of regulatory approval

7In addition, the Company issued 5% of the total number of issued and outstanding shares in the Company’s Series A financing to the same institution, or 1,652,632 shares in March 2016. ~~Subsequent~~This ~~Events:~~agreement, payable in Canadian dollars, exposes the Company to foreign exchange transaction gains and losses. In August 2016, the Company issued an additional 300,000 shares of the Company’s common stock to McGill in lieu of the pre-existing anti-dilution provision. As McGill owns more than 5% of the Company’s outstanding common stock, it is considered a related party.

Research Agreement – In ~~October~~January ~~2018~~2016 wethe ~~executed~~Company signed a ~~business~~Research ~~consulting~~Agreement ~~agreement~~ with aThe ~~new~~Research ~~member~~Institute of ~~our~~the ~~Scientific~~McGill ~~Advisory~~University Health ~~Board~~Centre ~~through~~(RIMUHC) ~~which~~in weCanada ~~issued~~for anresearch ~~immediately~~activities ~~exercisable~~on ~~warrant~~the toCompany’s ~~purchase~~potential upproducts. toThe ~~100,000~~agreement ~~shares~~covers a period of ~~our~~one ~~common~~year ~~stock~~and atrequired anthe ~~exercise~~Company ~~price~~to pay a total of $0130,000.01 ~~per~~The ~~share~~Agreement ~~for~~was aamended ~~period~~in ofMarch ~~five~~2017 ~~years~~to ~~from~~extend ~~issuance. This~~the ~~agreement has a~~ term offor one ~~three~~year ~~years~~ and ~~may~~required bethe ~~terminated~~payment byof ~~either~~an ~~party~~additional ~~with~~$130,000 ~~thirty~~over ~~days~~that ~~written notice~~period. In ~~addition,~~The ~~the~~Company ~~consultant~~paid ~~may~~these ~~earn~~installment ~~additional~~payments ~~warrants~~in ~~during~~July and ~~the~~October ~~term~~2017 ofleaving ~~the~~no ~~agreement~~balance ~~for~~due. ~~the~~The ~~exercise~~Company ofagreed upin June 2018 to ~~750,000~~an additional ~~shares,~~payment ~~with~~of ~~similar exercise terms~~$65,000 ~~based~~to oncontinue ~~certain~~research and ~~scientific~~development ~~milestones~~activities ~~for~~at ~~the~~RIMUHC ~~Company’s~~and ~~androgen~~signed ~~replacement~~an ~~treatment. We~~extension ~~anticipate~~of ~~there~~the ~~will~~agreement bein ~~stock~~January ~~based~~2019 ~~compensation~~requiring ~~expense~~an ~~related~~additional topayment of ~~this~~$35,000, ~~issuance~~which towas bepaid ~~booked~~ in ~~the~~April ~~three month period ending December 31, 2018~~2019.

On November 1, 2018, our Board of Directors (the “Board”) approved the adoption of the 2018 Stock Omnibus Plan (the “Plan”). The purpose of the Plan is to assist the Company in attracting and retaining selected individuals to serve as employees, directors, consultants and/or advisors who are expected to contribute to the Company’s success and to achieve long-term objectives that will benefit stockholders of the Company through the additional incentives inherent in the Awards thereunder. The Plan allows the Board of Directors, and its Compensation Committee (“Committee”) if formed, to Award up to 4,500,000 shares of the Registrant’s $0.0001 par value common stock through the issuance of Stock Options, Stock Appreciation Rights, Restricted Stock Grants, Performance Awards, and eligible Other Share-Based Awards. These Awards will occur from time-to-time, at the discretion of the Board or Committee on dates and in amounts to be determined, to any employee, director or consultant pursuant to the terms of the Plan. The Plan will not be effective, and no Awards can be issued, until approved by the Company’s stockholders. 10

12IASO BIOMED, INC.

~~IASO~~NOTES TO ~~BIOMED,~~UNAUDITED ~~INC.~~CONDENSED FINANCIAL STATEMENTS

~~NOTES~~Scientific Advisory TOBoard ~~UNAUDITED~~– ~~CONDENSED~~In ~~FINANCIAL~~September ~~STATEMENTS~~2018 we executed agreements with four new members of our Scientific Advisory Board (“SAB”) through which each new member received a warrant to purchase up to 35,000 shares of our common stock at an exercise price of $0.01 per share for a period of one year. In addition, each new SAB member will be paid an annual fee of $25,000, paid quarterly, commencing with the first scheduled SAB meeting that occurred November 2018. These agreements may be renewed annually, under the same terms and conditions, should each member’s appointment to the SAB be continued. In March 2019, 35,000 of these warrants were exercised by a member of our SAB.

~~Also on November 1, 2018, the Registrant’s Board approved the issuance of warrants to purchase shares of the Corporation’s common stock to two if its executive officers~~6. ~~Mr.~~ Share-based Duane C. Knight, Chief Financial Officer of the Registrant, received a warrant to purchase up to 950,000 shares of common stock exercisable for period of three months at an exercise price of $0.001 per share. Mr. Thomas B. Olson, Corporate Secretary of the Registrant, received a warrant to purchase up to 211,112 shares of common stock exercisable for period of three months at an exercise price of $0.001 per share. These warrants were not issued pursuant to the 2018 Stock Omnibus Plan.Compensation

~~Management~~In March ~~has~~2017, ~~determined~~the ~~that~~Company ~~there~~issued ~~are~~750,000 nowarrants ~~further~~to ~~events~~the ~~subsequent~~Company’s officers to ~~the~~purchase ~~balance~~shares ~~sheet~~of ~~date~~our ~~that~~common ~~should~~stock beat ~~disclosed~~$0.40 per inshare. ~~these~~Estimated ~~financial~~fair ~~statements.~~values of warrants granted were determined using the Black-Scholes option pricing model with the following average assumptions:

Risk-free interest rate		1.55	%
Expected term		3 years
Volatility		154	%
Dividend yield		-
Fair value	$	0.33

~~Item~~Expected term 2represents the period that the Company’s stock-based awards are expected to be outstanding. ~~Management~~The Company’s ~~Discussion~~historical stock ~~and~~warrant ~~Analysis~~exercise ofexperience ~~Financial~~does ~~Condition~~not ~~and~~provide ~~Results~~a ofreasonable ~~Operations~~basis upon which to estimate expected term. As such, the simplified method was used to calculate the expected term.

~~Overview~~The Company calculated volatility based on the volatilities of comparable public companies.

~~The following discussion should be read in conjunction with our Registration Statement on Form S~~Total share-1, and the financial statements and accompanying notes included in Part I, Item I of this Quarterly Report on Form 10-Q. The following discussion contains forward-looking statements made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, including the statements listed in the section below entitled Part II, Item 1A—Risk Factors. These statements are based oncompensation ~~our~~related ~~beliefs and expectations about future outcomes, and are subject~~ to ~~risks~~these ~~and~~warrants ~~uncertainties~~was ~~that could cause our actual results to differ materially from anticipated results. Factors that could cause or contribute to such differences include those described in Part II~~$20,502 ~~Item~~for ~~1A—Risk Factors of this Quarterly Report on Form 10-Q; factors described in our Registration Statement on Form S-1, under~~ the ~~section entitled Part I, Item 1A—Risk Factors—Forward~~three-~~Looking~~months ~~Statements;~~ended ~~and~~March ~~factors described in other cautionary statements~~31, ~~cautionary language and risk factors set forth in other filings with the Securities and Exchange Commission (SEC)~~2018. ~~We undertake no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.~~

~~IASO~~In February ~~BioMedÒ,~~and ~~Inc.~~March ~~(IASO~~2018 or the "Company") isissued awarrants ~~developmental~~to ~~stage~~purchase ~~biotechnology~~up ~~company~~to ~~focusing~~860,000 onshares ~~researching~~of ~~and~~common ~~developing~~stock ~~drugs~~at ~~and~~an ~~diagnostic~~exercise ~~tests~~price ~~for~~of ~~products with a large commercial market potential as well and/or and drugs that may qualify for orphan drug status~~$0.01 per ~~The~~share ~~Company is developing a drug for androgen replacement treatment that it believes will be a safer alternative~~ to ~~currently~~business, ~~available~~legal ~~testosterone~~and ~~replacement~~scientific ~~therapy~~consultants; ~~by stimulating the body's own testosterone production rather than using synthetic hormones and steroids~~400,000 ~~and developing an out~~ of ~~body~~which ~~test~~were to ~~identify~~expire ~~Alzheimer's~~in ~~disease.~~December ~~IASO~~2022 isand ~~also developing a process~~460,000 orof ~~method,~~ which expire ~~the~~in ~~Company~~February ~~believes will be the basis for developing an early stage blood or fluid test for Alzheimer's disease~~2021. ~~The~~Estimated ~~Company~~fair ~~was~~values ~~incorporated as a C-corporation in the state~~ of ~~Colorado~~warrants ongranted ~~March~~were ~~11,~~determined ~~2015.~~using Itthe ~~has~~Black-Scholes ~~its~~option ~~primary~~pricing ~~place~~model with ofthe ~~business~~following inaverage ~~Denver, Colorado.~~assumptions:

JOBS Act –We are an "emerging growth company" as defined in the recently-enacted JOBS Act, and we are eligible to take advantage of certain exemptions from various reporting and disclosure requirements that are applicable to public companies that are not "emerging growth companies." As an "emerging growth company" under the JOBS Act, we are permitted to, and intend to, rely on exemptions from certain reporting and disclosure requirements, which may make our future public filings different than that of other public companies.

Risk-free interest rate	2.33 – 2.34		%
Expected term	2.5 years
Volatility	182 – 217		%
Dividend yield		-
Fair value	$	0.39

~~Section~~Expected term ~~107~~represents of the ~~JOBS~~period ~~Act provides~~ that ~~an "emerging growth company" can take advantage of~~ the ~~extended~~Company’s ~~transition~~stock-based ~~period~~awards ~~provided~~are inexpected Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an "emerging growth company" can delay the adoption of certain new accounting standards until those standards would otherwise apply to ~~private~~be ~~companies~~outstanding. WeThe ~~have~~Company’s ~~elected~~historical stock towarrant ~~use~~exercise ~~the~~experience ~~extended~~does ~~transition~~not ~~period~~provide ~~for~~a ~~complying~~reasonable ~~with~~basis ~~new~~upon orwhich ~~revised accounting standards under Section 102(b)(2) of the JOBS Act, that allows us~~ to ~~delay~~estimate ~~the~~expected ~~adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies~~term. As ~~a result of this election~~such, ~~our~~the ~~financial~~simplified method ~~statements~~was ~~may~~used ~~not be comparable~~ to ~~companies~~calculate ~~that~~the ~~comply~~expected ~~with public company effective dates~~term.

WeThe Company ~~will~~calculated ~~remain~~volatility anbased ~~"emerging~~on ~~growth company" until~~ the ~~earliest~~volatilities of: ~~(i)~~comparable ~~the~~public last day of the fiscal year during which we had total annual gross revenues of $1 billion or more, (ii) the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement, (iii) the date on which we have, during the previous 3-year period, issued more than $1 billion in non-convertible debt or (iv) the date on which we are deemed a "large accelerated filer" as defined under the federal securities lawscompanies.

WeTotal share-based ~~have~~compensation ~~not~~related ~~generated~~to ~~any~~these ~~revenue~~warrants towas ~~date~~$336,926 ~~and~~for wethe dothree ~~not~~months ~~currently~~ended ~~have~~March a31, ~~product ready for sale~~2018.

14We incurred no share-based compensation in the three-month period ended March 31, 2019.

~~At September 30, 2018 and December 31, 2017, the Company had cash of $177,692 and $20,191, respectively~~7. Subsequent It also had a working capital deficit of $418,141 and $292,377, respectively and an accumulated deficit of $2,353,746 and $1,403,928, respectively. Our losses have principally been operating expenses incurred in startup research and development costs, general and administrative, legal, and intellectual property expenses. We expect to continue to incur substantial costs for these activities over at least the next year. Management is taking action to ensure the Company will continue as a going concern for at least one year beyond the date of the issuance of the Company’s financial statements. From March 11, 2015 (Inception) through September 30, 2018, the Company has sold $971,842 in common stock. Common stock sales continue pursuant to the Company’s private placement offering. Additionally, the Company received approval for its Form S-1 Registration Statement with the Securities and Exchange Commission, through which it may offer for sale additional shares of its common stock.Events:

IfManagement has wedetermined ~~are~~that ~~unable~~there toare ~~obtain~~no ~~additional~~further ~~financing~~events onsubsequent ~~a timely basis, we may have~~ to ~~curtail~~the ~~our~~balance ~~development,~~sheet ~~and~~date ~~business~~that ~~activities,~~should ~~which would have a material adverse effect on our business, financial condition and results of operations, and ultimately, we could~~ be ~~forced~~disclosed toin ~~discontinue~~these ~~our operations and liquidate~~financial statements. ~~See "Liquidity and Capital Resources" below.~~

~~Results of Operations~~11

~~Nine~~Item 2. ~~months~~Management’s ~~ended~~Discussion ~~September~~and ~~30,~~Analysis ~~2018~~of ~~compared~~Financial toCondition ~~nine~~and ~~months~~Results ~~ended~~of ~~September 30, 2017~~Operations.

~~The following table presents a summary of our statements of operations for the nine months ended September 30, 2018 and 2017.~~Overview

	For the Nine Months Ended
	September 30,
	2018		2017
Revenues		$ -		$ -
Operating Expenses		947,125		602,016
Loss from Operations		(947,125)		(602,016)
Other Expenses		(2,693)		(1,121)
Net Loss		$ (949,818)		$ (603,137)
Earnings per Common Share:
Basic and Diluted		$ (0.03)		$ (0.02)
Weighted Average Number of Common Shares Outstanding
Basic and Diluted		34,794,024		33,716,070

IASO BioMed®, Inc. (IASO or the “Company”) is a developmental stage biotechnology company focusing on researching and developing drugs and diagnostic tests for products with a large commercial market potential as well and/or and drugs that may qualify for orphan drug status. The Company primarily is developing a drug that it believes will be a safer alternative to currently available testosterone replacement therapy by stimulating the body’s own testosterone production rather than using synthetic hormones and steroids; and secondarily developing an out of body test to identify Alzheimer’s disease. IASO is also developing a process, or method, which the Company believes will be the basis for developing an early stage blood or fluid test for Alzheimer’s disease. The Company was incorporated as a C-corporation in the state of Colorado on March 11, 2015. It has its primary place of business in Denver, Colorado.

~~Revenues~~JOBS Act –We are an “emerging growth company” as defined in the recently-enacted JOBS Act, and we are eligible to take advantage of certain exemptions from various reporting and disclosure requirements that are applicable to public companies that are not “emerging growth companies.” As an “emerging growth company” under the JOBS Act, we are permitted to, and intend to, rely on exemptions from certain reporting and disclosure requirements, which may make our future public filings different than that of other public companies.

~~The~~Section 107 ~~Company~~of ~~was~~the ~~incorporated~~JOBS onAct ~~March~~provides 11that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, ~~2015~~an “emerging ~~and~~growth ~~has~~company” nocan ~~revenues~~delay the adoption of certain new accounting standards until those standards would otherwise apply to~~-date~~ ~~and~~private ~~has~~companies. noWe ~~products~~have ~~ready~~elected to use the extended transition period for ~~sale~~complying with new or revised accounting standards under Section 102(b)(2) of the JOBS Act, that allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.

~~General~~We will ~~and~~remain ~~administrative~~an “emerging growth company” until the earliest of: (i) the last day of the fiscal year during which we had total annual gross revenues of $1 billion or more, (ii) the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement, (iii) the date on which we have, during the previous 3-year period, issued more than $1 billion in non-convertible debt or (iv) the date on which we are deemed a “large accelerated filer” as defined under the federal securities laws.

~~General~~We have ~~and~~not ~~administrative~~generated ~~expenses~~any ~~consist~~revenue ~~primarily of professional legal and accounting fees related~~ to ~~the preparation and filing of the Company’s Form S-1 registration statement and Form 10-Qs and Form 10-K~~date, and ~~compensation.~~we ~~Total~~do ~~general~~not ~~and~~currently ~~administrative~~have ~~expenses~~a ~~increased~~product byready ~~$412,685 the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017. The primary reason~~ for ~~the increase is the recording of share-based compensation of $412,304 in 2018 compared to $193,693 in 2017, and Scientific Advisory Board fees of $135,000 in 2018 and none in 2017~~sale. ~~We expect that our general and administrative expenses will increase as we expand our staff, develop our infrastructure and incur additional costs to support the execution of our business plan.~~

~~The~~At March 31, 2019 and December 31, 2018, the Company ~~incurred~~had cash of $1078,~~804~~174 and $9140,~~846~~234, respectively. It also had a working capital deficit of $790,667 inand ~~intellectual~~$602,519, ~~property~~respectively ~~expenses~~and an accumulated deficit of $3,231,824 and $3,041,165, respectively. This raises substantial doubt about the Company’s ability to continue as a going concern. Management is taking action to ensure the Company will continue as a going concern for at least one year beyond the ~~nine~~date ~~months~~of ~~ended~~the ~~September~~issuance 30of the Company’s financial statements. From March 11, ~~2018~~2015 (Inception) through March 31, 2019, the Company sold $971,842 in common stock. Common stock sales continue pursuant to private placement and ~~2017~~other potential equity offerings. These fundraising efforts may not be successful. While there can be no assurances, management believes that ~~are~~these ~~included~~actions will enable the Company to continue as ~~general~~a ~~and~~going ~~administrative~~concern. The ~~expenses~~financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

15If we are unable to obtain additional financing on a timely basis, we may have to curtail our development, and business activities, which would have a material adverse effect on our business, financial condition and results of operations, and ultimately we could be forced to discontinue our operations and liquidate. See “Liquidity and Capital Resources” below.

~~Research and development~~12

~~Research~~Results of and development costs are charged to operations in the period incurred. For nine months ended September 30, 2018 and 2017, total research and development expenses were $95,000 and $162,576, respectively.Operations

~~Interest~~Three-months ended ~~expense~~March 31, 2019 compared to three-months ended March 31, 2018

~~For~~The following ~~the~~table ~~nine~~presents ~~months~~a ~~ended~~summary ~~September~~of ~~30,~~our ~~2018~~statements ~~and 2017, the Company accrued interest expense~~ of ~~$2,693~~operations ~~and $1,121, respectively,~~ for ~~note~~the ~~payable~~three ~~related~~months ~~party~~ended ~~totaling~~March ~~$60~~31,~~000~~ ~~during~~2019 ~~that period which was outstanding at September 30, 2018~~ and ~~December 31, 2017~~2018.

Liquidity and Capital Resources

	For the Three-months Ended
	March 31,
	2019			2018
Revenues	$	-		$	-
Operating Expenses		189,771			555,357
Loss from Operations		(189,771	)		(555,357	)
Other Expenses		(888	)		(888	)
Net Loss	$	(190,659	)	$	(556,245	)
Earnings per Common Share:
Basic and Diluted	$	(0.01	)	$	(0.02	)
Weighted Average Number of Common Shares Outstanding
Basic and Diluted		37,048,417			34,537,632

~~We measure our liquidity in a number of ways, including the following:~~Revenues

	September 30, 2018		December 31, 2017
Cash		$ 177,692		$ 20,191
Working Capital Deficit		$ (418,141)		$ (292,377)

The Company was incorporated on March 11, 2015 and has no revenues to-date and has no products ready for sale.

~~Since our inception, we have not generated any revenues~~ General and have funded our operations through the sale of our equity securities and through notes payable from the Company’s CEO. The implementation of our business plan, as discussed in "Business," will require the receipt of sufficient grant, equity and/or debt financing to purchase necessary technology and materials, fund our research and development efforts, and otherwise fund our operations. If we are able to complete our offering under the recently approved Form S-1 Registration Statement in full, we anticipate that the estimated net proceeds of $4,800,000 from that offering (assuming no underwriter or brokerage commissions are paid in connection with the offering) will fund our operations until at least December 31, 2018.administrative

	For the nine months ended September 30,
	2018		2017
Cash (used in) provided by:
Operating activities		$ (254,249)		$ (192,844)
Financing activities		$ 411,750		$ 214,000

General and administrative expenses consist primarily of professional legal and accounting fees related to the preparation and filing of the Company’s Form 10-Qs and Form 10-K, and compensation. Total general and administrative expenses decreased by $402,586 the three-months ended March 31, 2019 compared to the three-months ended March 31, 2018. The primary reason for the decrease is the recording of share-based compensation of $540,347 in 2018 compared to no similar expense in 2019, and Scientific Advisory Board fees of $105,000 in 2018 and $15,000 in 2019. We expect that our general and administrative expenses will increase as we expand our staff, develop our infrastructure and incur additional costs to support the execution of our business plan, however, issuances of stock compensation may not occur on a regular basis and may therefore result in significant swings in general and administrative expense from quarter-to-quarter.

~~Net~~The Company ~~Cash~~incurred ~~Used~~$5,366 and $0, respectively, in ~~Operating~~intellectual ~~Activities~~property expenses for the three months ended March 31, 2019 and 2018 that are included as general and administrative expenses. In addition, we accrued $3,750 in license fees in the three-month period ended March 31, 2019 for payments under our License Agreement with McGill University.

~~For the nine months ended September 30, 2018~~ Research and 2017, we experienced negative cash flows from operating activities of $254,249 and $192,844, respectively. This is due primarily to a net loss of $949,818 and $603,137, respectively. The loss for the nine months ended September 30, 2018 is reduced by share-based compensation of $412,304, accrued Scientific Advisory Board fees of $125,000, accrued salaries of $158,750, a decrease in accounts payable of $1,838 and accrued interest expense of $2,693, less a decrease in increase of prepaid expenses of $1,340. For the nine months ended September 30, 2017 the loss is reduced by share-based compensation of $193,693, an increase in accounts payable of $80,808, accrued salaries of $131,250, non-cash contributed services of $5,000, less a change in prepaid expenses of $1,576. We anticipate that we will continue to use cash in operating activities in the near future.development

16Research and development costs are charged to operations in the period incurred. For three months ended March 31, 2019 and 2018, total research and development expenses were $35,000 and $10,000, respectively.

~~Net Cash Provided by Financing Activities~~Interest expense

~~Net~~For each ~~cash~~of ~~provided by financing activities for~~ the ~~nine~~ three months ended ~~September~~March 3031, ~~2018~~2019 and ~~2017 totaled $411~~2018,~~750~~ ~~and~~the ~~$214,000,~~Company ~~respectively,~~accrued asinterest aexpense ~~result~~ of ~~common~~$888 ~~stock~~for ~~sales~~note inpayable ~~both~~related party ~~years~~totaling ~~and~~$60,000 ~~warrant~~during ~~exercises~~that inperiod ~~2018.~~which Wewas ~~continue~~outstanding toat ~~seek~~March ~~additional~~31, ~~funding~~2019 ~~through our private placement~~ and ~~through~~December a31, ~~public offering~~2018.

For the nine months ended September 30, 2018 the Company sold $417,500 in private placements, issuing 1,275,000 shares of our common stock at an average price of $0.32 per share. There were also 425,000 shares issued for an exercise of warrants for proceeds of $4,250. For the nine months ended September 30, 2017, the Company issued 525,000 shares of commons stock for total proceeds of $211,500 through placements of common stock as well as issued 250,000 common shares through warrant exercises for proceeds totaling $2,500.13

~~Three~~Liquidity and ~~months~~Capital ~~ended September 30, 2018 compared to three months ended September 30, 2017~~Resources

~~The~~We measure ~~following~~our ~~table~~liquidity ~~presents~~in a ~~summary~~number of ~~our~~ways, ~~statements~~including ~~of operations for~~ the ~~three months ended September 30, 2018 and 2017.~~following:

	For the Three Months Ended
		March 31, 2019				December 31, 2018
	September 30,
Cash		$	78,174			$	140,234
	2018			2017
Working Capital Deficit		$	(790,667	)		$	(602,519	)
Revenues		$ -			$ -
Operating Expenses		196,975			125,286
Loss from Operations		(196,975)			(125,286)
Other Expenses		(907)			(377)
Net Loss		$ (197,882)			$ (125,663)
Earnings per Common Share:
Basic and Diluted		$ (0.01)			$ (0.00)
Weighted Average Number of Common Shares Outstanding
Basic and Diluted		35,358,882			34,164,116

~~Revenues~~Since our inception, we have not generated any revenues and have funded our operations through the sale of our equity securities and through notes payable from the Company’s CEO. The implementation of our business plan, as discussed in “Business,” will require the receipt of sufficient grant, equity and/or debt financing to purchase necessary technology and materials, fund our research and development efforts, and otherwise fund our operations. We are currently seeking funding of up to $6,000,000 to fund our operations for a period of 18 to 24 months, approximately $1,000,000 of which should fund our operations until at least December 31, 2019.

The Company was incorporated on March 11, 2015 and has no revenues to-date and has no products ready for sale.

	For the three-months ended March 31,
	2019			2018

Cash (used in) provided by:
Operating activities	$	(64,571	)	$	(66,202	)
Financing activities	$	2,511		$	104,000

~~General~~Net Cash ~~and~~Used ~~administrative~~in Operating Activities

~~General~~For the ~~and~~three ~~administrative~~months ~~expenses~~ended ~~consist~~March ~~primarily~~31, of2019 ~~professional legal~~ and ~~accounting~~2018, ~~fees~~we ~~related~~experienced tonegative ~~the~~cash ~~preparation~~flows ~~and~~from ~~filing~~operating activities of ~~the~~$64,571 ~~Company’s~~and ~~Form~~$66,202, respectively. ~~S-1~~This ~~registration~~is ~~statement~~due ~~and~~primarily ~~Form~~to ~~10-Qs~~a ~~and~~net ~~Form~~loss ~~10-K~~of $190,659 and ~~compensation~~$556,245, respectively. ~~Total~~The ~~general~~loss ~~and~~for ~~administrative~~the ~~expenses~~three-months ~~increased~~ended March ~~$73~~31,~~187~~ ~~for~~2019 ~~the~~is ~~three~~reduced ~~months~~primarily ~~ended~~by ~~September~~share-based ~~30,~~accrued ~~2018~~Scientific ~~compared~~Advisory toBoard ~~the~~fees ~~three~~of ~~months~~$15,000, ~~ended~~accrued ~~September~~salaries 30of $56,250 and ~~2017~~accounts ~~primarily~~payable ~~due~~of to $5452,~~876~~499. inFor ~~stock~~the ~~compensation~~three-months ~~cost~~ended ~~from~~March 31, 2018 the ~~issuance~~loss is reduced primarily by share-based compensation of ~~warrants~~$357,428, inaccrued ~~2018.~~salaries Weof ~~expect~~$56,250, ~~that~~Scientific ~~our~~Advisory ~~general~~Board ~~and~~fees ~~administrative~~of ~~expenses~~$105,000, ~~will~~less ~~increase~~a asdecrease wein ~~expand~~accounts ~~our~~payable ~~staff~~of $30,930. We ~~develop~~anticipate ~~our~~that ~~infrastructure~~we ~~and~~will ~~incur~~continue ~~additional~~to ~~costs~~use tocash ~~support~~in ~~the~~operating ~~execution~~activities offor ~~our~~the ~~business~~foreseeable ~~plan~~future.

~~The~~Net Cash ~~Company~~Provided ~~incurred~~by ~~$8,548~~Financing ~~and $1,315, respectively, in intellectual property expenses for the three months ended September 30, 2018 and 2017 that are included as general and administrative expenses.~~ Activities

~~Research~~Net cash provided by financing activities for the three months ended March 31, 2019 and ~~development~~2018 totaled $2,511 and $104,000, respectively, as a result of warrant exercised in 2019 and common stock sales and warrant exercises in 2018. We continue to seek additional funding through private placement offerings.

~~Research~~For the ~~and~~three-months ~~development~~ended ~~costs~~March ~~are~~31, ~~charged~~2019 tothe ~~operations~~Company inissued 1,296,112 shares through the ~~period~~exercise ~~incurred.~~of warrants for proceeds of $2,511. For ~~three~~the three-months ended ~~September~~March 3031, 2018, ~~and~~the ~~2017~~Company issued 250,000 ~~total~~shares ~~research~~of ~~and~~commons ~~development~~stock ~~expenses~~for ~~were~~total proceeds of $10100,000 ~~and~~through placements ~~$11~~of common stock as well as issued 400,~~498,~~000 ~~respectively~~common shares through warrant exercises for proceeds totaling $4,000.

17Off-Balance Sheet Arrangements

~~Interest~~We have ~~expense~~not entered into any other financial guarantees or other commitments to guarantee the payment obligations of any third parties other than as described following under “Contractual Obligations.” We have not entered into any derivative contracts that are indexed to our shares and classified as stockholders’ equity or that are not reflected in our financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

~~For~~Item 3. ~~the~~Quantitative ~~three months ended September 30, 2018~~ and ~~2017,~~Qualitative ~~the~~Disclosures ~~Company~~about ~~accrued~~Market ~~interest expense of $907 and $377, respectively, for note payable related party totaling $60,000 during that period which was outstanding at September 30, 2018 and December 31, 2017.~~Risk

~~Off-Balance Sheet Arrangements~~Not applicable.

We have not entered into any other financial guarantees or other commitments to guarantee the payment obligations of any third parties other than as described following under “Contractual Obligations.” We have not entered into any derivative contracts that are indexed to our shares and classified as stockholders’ equity or that are not reflected in our financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us. 14

Item 3 4. ~~Quantitative~~Controls and ~~Qualitative Disclosures about Market Risk~~Procedures.

~~Not~~Disclosure Controls ~~applicable~~and Procedures.

~~Item~~Our management 4including our CEO and CFO, who act as our principal executive officer and principal financial officer, respectively, evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this report. ~~Controls~~Disclosure controls and ~~Procedures~~procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our CEO and CFO concluded that, as of March 31, 2019, our disclosure controls and procedures were not effective as of such date because due to the small size and limited financial resources, our chief financial officer, corporate secretary and chief executive officer are the only individuals involved in the accounting and financial reporting. As a result, the Company lacks sufficient accounting personnel to ensure the accurate and timely filing of its periodic reports. This limited segregation of duties represents a material weakness.

~~Disclosure~~Changes in ~~Controls~~Internal ~~and~~Control ~~Procedures~~over Financial Reporting.

~~Our~~There were ~~management~~no ~~including~~changes ~~our~~in ~~CEO and CFO, who act as~~ our ~~principal~~internal ~~executive~~control ~~officer~~over ~~and principal~~ financial ~~officer,~~reporting ~~respectively,~~(as ~~evaluated~~such ~~the~~term ~~effectiveness~~is ~~of our disclosure controls and procedures as~~ defined in Rules 13a-15(ef) and 15d-15(ef) ~~under~~ of the Exchange Act) asthat ofoccurred ~~the~~during ~~end of~~ the ~~period~~quarter ~~covered~~ended byMarch ~~this report. Disclosure controls and procedures include~~31, ~~without limitation~~2019, ~~controls and procedures designed to ensure~~ that ~~information~~have ~~required~~materially toaffected, ~~be disclosed by us in the reports that we file~~ or ~~submit~~are ~~under~~reasonably ~~the~~likely to ~~Exchange~~materially ~~Act is recorded~~affect, ~~processed,~~our ~~summarized~~internal ~~and~~control ~~reported~~over ~~within~~financial ~~the~~reporting. ~~time~~In ~~periods~~designing ~~specified~~and inevaluating the ~~SEC’s~~disclosure ~~rules~~controls and ~~forms~~procedures, management ~~and~~recognizes that ~~such~~any ~~information~~controls ~~is accumulated~~ and ~~communicated to our management as appropriate~~procedures, tono ~~allow~~matter ~~timely~~how ~~decisions~~well ~~regarding~~designed ~~required disclosure. Based on this evaluation, our CEO~~ and ~~CFO concluded that~~operated, ascan ofprovide ~~September~~only ~~30,~~reasonable assurance ~~2018, our disclosure controls and procedures were not effective as~~ of ~~such~~achieving ~~date because due to~~ the ~~small~~desired ~~size~~control ~~and~~objectives. ~~limited~~In ~~financial resources~~addition, ~~our~~the ~~chief~~design ~~financial~~of ~~officer,~~disclosure ~~corporate~~controls ~~secretary~~ and ~~chief~~procedures ~~executive~~must ~~officer are~~ reflect the ~~only~~fact ~~individuals~~that ~~involved~~there inare ~~the~~resource ~~accounting~~constraints and ~~financial~~that ~~reporting.~~management Asis arequired ~~result, the~~to ~~Company~~apply ~~lacks~~its ~~sufficient~~judgment ~~accounting~~in ~~personnel~~evaluating ~~to ensure~~ the ~~accurate and timely filing~~ benefits of ~~its~~possible ~~periodic~~controls ~~reports. This~~and ~~limited~~procedures ~~segregation~~relative ofto ~~duties~~their ~~represents a material weakness~~costs.

~~Changes~~PART II. inOTHER ~~Internal Control over Financial Reporting.~~INFORMATION

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the quarter ended September 30, 2018, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reportingItem 1. InLegal designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.Proceedings

18None.

~~PART II~~Item 1A. ~~OTHER~~Risk ~~INFORMATION~~Factors

~~Item~~You should 1.consider ~~Legal~~carefully ~~Proceedings~~the factors discussed in the “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018, which could materially affect our business.

~~None~~Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

~~Item 1A~~None. ~~Risk Factors~~

~~You~~Item 3. ~~should~~Defaults ~~consider~~Upon ~~carefully~~Senior ~~the factors discussed in the “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017, which could materially affect our business.~~Securities

~~Item 2~~None. ~~Unregistered Sales of Equity Securities and Use of Proceeds~~

~~In September 2018, the Company issued 125,000 shares of our $0~~Item 4.~~0001~~ ~~par~~Mine ~~value~~Safety common stock at $0.30 per share for total proceeds to the Company of $37,500 that included warrants to purchase up to 125,000 shares of our common stock exercisable at $0.05 per share for a period of three years from issuance.Disclosures

~~We offered and sold the securities in reliance on an exemption from federal registration under Section 4(2) of the Securities Act of 1933 and Rule 506 promulgated thereunder~~Not applicable.

Item 3 5. ~~Defaults~~Other ~~Upon Senior Securities~~Information

None.

~~Item 4. Mine Safety Disclosures~~15

~~Not applicable~~Item 6. Exhibits

~~Item~~Exhibits filed 5.as ~~Other~~a ~~Information~~part of this Quarterly Report on Form 10-Q are listed on the Exhibit Index, which is incorporated by reference herein.

~~None.~~Exhibits:

Item 6. Exhibits

31.1	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed herewith.

31.2	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed herewith.

32.1	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Filed herewith.

10.1	Interactive data files pursuant to Rule 405 of Regulation S-T.

~~Exhibits filed as a part of this Quarterly Report on Form 10-Q are listed on the Exhibit Index, which is incorporated by reference herein.~~16

~~Exhibits:~~SIGNATURES

31.1	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed herewith.
31.2	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed herewith.
32.1	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Filed herewith.
101	Interactive data files pursuant to Rule 405 of Regulation S-T.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	IASO BioMed, Inc.
	(Registrant)

Date: May 17, 2019	By:	/s/ Mr. Richard Schell
		Mr. Richard Schell
		Chief Executive Officer
		(Principal Executive Officer)

Date: May 17, 2019	By:	/s/ Mr. Duane Knight
		Mr. Duane Knight
		Chief Financial Officer
		(Principal Accounting Officer)

~~SIGNATURES~~17

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	IASO BioMed, Inc.
	(Registrant)
Date: November 19, 2018	By:	/s/ Mr. Richard Schell
		Mr. Richard Schell
		Chief Executive Officer
		(Principal Executive Officer)
Date: November 19, 2018	By:	/s/ Mr. Duane Knight
		Mr. Duane Knight
		Chief Financial Officer
		(Principal Accounting Officer)

Filing Compare · IASO BioMed, Inc.